OUR SCIENCE

We are driven to wake up a dormant therapeutic area and usher in a new era of treatment for patients with acid-related disorders

Medical Information

Phathom Pharmaceuticals is currently evaluating vonoprazan* (potassium-competitive acid blocker) for the treatment of H. pylori infection, erosive GERD, and non-erosive reflux disease (NERD).

Learn more about the acid-related disease landscape we are committed to evolving, including our robust clinical programs and late-stage research.

Connect with our Medical Team

*Vonoprazan is a product candidate that is under clinical study and that has not been approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of vonoprazan.